Organised by SHC
The Science of HBV Cure Meeting 2026 LIVE
For Scientists, Clinician Scientists and
Pharmacists and Industry Experts
4 – 5 September 2026
8.30am – 6.00pm SGT
The Science of HBV Cure Meeting 2026 LIVE
Register for Live Meeting
By registering for The Science of HBV Cure Meeting 2026, you are automatically enrolled for the SHC 2026 Online Meeting.
Who Should Attend?
The Science of HBV Cure Meeting is important for patients, doctors, scientists and pharmaceutical companies seeking to understand Hepatitis B and its new treatments. In particular, Hepatitis B cure is becoming a reality with new drugs tested in phase 3 clinical trials.
Additionally, Hepatitis D is also emerging as a disease for which therapy is rapidly evolving. The Science of HBV Cure Meeting will also discuss the emerging treatments for HDV.
The Science of HBV Cure Meeting 2026 LIVE Scientific Programme
Speakers names will be added soon.
| 4 September 8.30am – 6.00pm SGT |
|
|---|---|
| The Science of Functional Cure | 8.30am To 12.30pm |
| New Antiviral Therapies | 14.00pm To 18.00pm |
| 5 September 8.30am – 6.00pm SGT |
|
|---|---|
| Immune Modulation in CHB | 8.30am To 12.30pm |
| The Future of HBV Functional Cure | 14.00pm To 18.00pm |
September, 2026
4
| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | 08:30 – 08:35 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Fabien Zoulim View Bio Prof. Jinlin Hou |
|
| HBV Cure: HBV Cure States from the Asian Consensus Conference – Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
08:35 – 09:00 |
| Challenges to achieve functional cure Adj. Prof. Veronica Miller, UC Berkeley, Public Health, USA View Bio |
09:00 – 09:20 |
| Landscape of functional cure 2026 after Bepirovirsen phase 3 results – Prof. Fabien Zoulim, Universite Claude Bernard Lyon 1, France View Bio |
09:20 – 09:45 |
| Q&A | 09:45 – 10:00 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Fabien Zoulim View Bio Prof. Jinlin Hou |
|
| Free paper: Clinically meaningful functional cure rates in virologically suppressed Chinese patients with chronic hepatitis B virus infection treated with bepirovirsen: A subanalysis of the B-Well Phase 3 trials, Prof. Jin Lin Hou, Nanfang University, Guangzhou, China |
10:00 – 10.15 |
| Free paper: Projected impact of hepatitis B virus functional cure therapies on liver disease burden in China: A modelling analysis, Dr. Devin Razavi-Shearer |
10:15 – 10.30 |
| Free paper: Metabolic Dysfunction and Its Impact on Chronic Hepatitis B Progression Hepatitis B Functional Cure: Real-World Clinical Perspectives, Dr. Preeti, Agarwal |
10.30 – 10:45 |
| Q&A | 10.45 – 11:00 |
| Tea Break | 11:00 – 11:15 |
| Virological Insights into functional cure Moderators: Prof. Thomas View Bio |
|
| Virological Cure and complete cure: achievable or imaginary? – Prof. Massimo Levrero, Universite Claude Bernard Lyon 1, France View Bio |
11:15 – 11:35 |
| Integrated HBV: what’s important? Burden, integration site or clonal expansion – Prof. Thomas Tu, Westmead Institute for Medical Research, Australia View Bio |
11:35 – 11:55 |
| Free paper : Intrahepatic viral integration more than reservoir size dictates the HBsAg loss trajectory in Chronic Hepatitis B, Dr. Cameron Soulette |
11:55 – 12:10 |
| Q&A | 12:10 – 12:20 |
| Lunch | 12:20 – 13:00 |
| Poster Presentation | 13:00 – 13:45 |
| Intrahepatic microenvironment Moderator: Prof. Massimo Levrero View Bio |
|
| Spatial transcriptomics: state of the Science and Art – Charting the Spatial Whole Transcriptome and Multiomic Frontier for Complete Biology Dr. Prajan Divakar, Bruker Corporation |
13:45 – 14:05 |
| Spatial proteomics: Advancements in cyclic immunofluorescence methods for liver tissue imaging and spatial profiling enabled by the CellScape XR platform. Dr. Benton Berigan, Bruker Corporation |
14:05 – 14:25 |
| Spatial Transcriptomics in HBV – Prof. Jane McKeating, Oxford |
14:25 – 14:50 |
| Intrahepatic immune correlates of functional cure – Prof. Adam Gehring, University of Toronto, Canada View Bio |
14:50 – 15:10 |
| Free paper: Spatial Transcriptomics of CHB and HBsAg loss using CosMx, Dr. Aravind Sivakumar et al |
15:10 – 15:25 |
| Q&A | 15:25 – 15:40 |
| Tea Break | 15:40 – 16:00 |
| Animal Models Moderator: Prof. Qingfeng Chen View Bio |
|
| Benefits and limitations of animal models to assess antivirals and immune modulators for Functional Cure. Prof. Maura Dandri, University Medical Center Hamburg-Eppendorf Germany View Bio |
16:00 – 16:20 |
| Free paper: Impact of Bulevirtide on Hepatocyte Transcriptional Programs in a Humanized Mouse Model of HDV Infection. Dr. Wakae Kousho (abstract 48) |
16:20 – 16:35 |
| Q&A | 16:35 – 16:45 |
| Delta Cure Moderator: Prof. Pietro Lampertico View Bio |
|
| Delta Cure update – Prof. Heiner Wedemeyer, Hannover Medical School, Germany View Bio |
16:45 – 17:05 |
| Novel therapeutics for Delta Cure Prof. Pietro Lampertico, Italy View Bio |
17:05 – 17:25 |
| Q&A | 17:25 – 17:35 |
| End of day 1 | 17:35 |
September, 2026
5
| Programme | Time (SGT) |
|---|---|
| Biomarkers Moderators: Prof. Teerha Piratvisuth View Bio |
|
| HBsAg levels in real world and for clinical trials of novel therapies – Prof. Man-Fung Yuen, Hong Kong View Bio |
08:30 – 08:50 |
| Biomarkers that corelate with cccDNA – Prof. Jordan Feld, University of Toronto, Canada View Bio |
08:50 – 09:10 |
| Using Biomarkers for management of CHB with novel therapies – Prof. Yasuhito Tanaka, Kumamoto University View Bio |
09:10 – 09:30 |
| Q&A | 09:30 – 09:40 |
| RNA interference Moderators: Prof. Mala Maini View Bio |
|
| Anti-sense oligonucleotides: are they immune modulators? – Prof. Antonio Bertoletti, Duke NUS Graduate School of Medicine, Singapore View Bio |
09 40 – 10:00 |
| The role of siRNA in HBV cure therapies – Prof. MF Yuen, Hong Kong University, Hong Kong View Bio |
10:00 – 10:20 |
| Q&A | 10:20– 10:30 |
| Tea Break | 10:30 – 10:45 |
| Poster Presentation | 10:45 – 11:00 |
| Strategies with existing agents Moderator: Prof. Seng Gee Lim View Bio |
|
| Stopping nucleoside analogues: is there still a role in FC? – Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
11:00 – 11:20 |
| Peginterferon: never say die – Prof. Teerha Piratsuvith, Prince of Songkla University, Thailand View Bio |
11:20 – 11:40 |
| Free paper To Stop or Not to Stop? End-of-Treatment HBcrAg for Predicting Relapse After Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B: A Diagnostic Test Accuracy Meta-Analysis. Budiman et al (abstract 35) |
11:40 – 11:55 |
| Q&A | 11:55 – 12:10 |
| Lunch | 12:10 – 13:10 |
| Invited Pharma Presentations Moderators: Prof. Lim Seng Gee View Bio and Prof. Adam Gehring View Bio |
|
| Bepirovirsen: The Journey So Far Attila Mihalyi (Vice President, Global Medical Lead, Hepatitis B) GSK |
13:10 – 13:25 |
| AHB-137, update Dr. Guo Feng Cheng, CEO, Ausperbio Therapeutics Inc |
13:25 – 13:40 |
| siRNA+Neutralizing antibody – Dr. Wu Kai, CEO, Hepa Thera Biopharmaceutical Co., Ltd |
13:40 – 13:55 |
| VRON-0200: Priming Immunity for CHB Cure: A Clinical Update Dr. Sue Currie, COO, Virion Therapeutics LLC |
13:55 – 14:10 |
| Q&A | 14:10 – 14:20 |
| Immunology Moderator: Prof. Antonio Bertoletti View Bio |
|
| The challenges and promise of immune modulation for FC – Prof. Mala Maini, University College London, UK View Bio |
14:20 – 14:40 |
| Antibody therapeutics in the quest for Functional Cure – Prof. Adam Gehring, University of Toronto, Canada View Bio |
14:40 – 15:00 |
| Free paper: Characterisation and discovery of epitopes of anti-HBe during HBeAg seroconversion, Dr. Low Heng Boon et al |
15:00 – 15:15 |
| Free paper: Peg-interferon modulates the trajectory of peripheral immunity in functionally cured chronic hepatitis B patients, Neo et al (abstract 26) |
15:15 – 15:30 |
| Free paper: First-in-Human Safety of the Dendritic Cell–Targeting Immunotherapy SN2001 with Translational Evidence Supporting Restoration of HBV-Specific Cellular Immunity, Shi et al (abstract 50) |
15:30 – 15:45 |
| Q&A | 15:45 – 16:00 |
| Tea Break | 16:00 – 16:15 |
| Gene Therapy Moderators: Prof. Fabien Zoulim View Bio |
|
| Early clinical results of gene/epigenetic editing – Prof. Ed Gane, University of Auckland, New Zealand View Bio |
16:15 – 16:35 |
| The safety of gene editing: What to measure and for how long? – Dr. Wei Leong Chew GIS, ASTAR View Bio |
16:35 – 16:55 |
| Q&A | 16:55 – 17:10 |
| Closing remarks from Chairman | 17:10 – 17.15 |
Call for Abstracts
Submission Deadline: 7 July 2026
We invite all interested parties to present their research papers. (abstracts of Case Studies will not be accepted) Click on below Abstracts and Posters for further information.
Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on Abstract & Poster Gallery in our website and in the Poster Hall. Presenters of oral presentations of accepted Abstracts as Free Papers will receive USD800 and a registration fee refund to help defray the cost of travel and accommodation here in Singapore. This payment will be made after the presentation.
Only abstracts of research papers will be accepted. Abstracts of Case Studies will not be accepted.